Assessing response to chemotherapy in metastatic melanoma with FDG PET: Early experience

Nuclear Medicine Communications

Volumn 28, Issue 12, 2007, Pages 902-906

  Hofman, Michael S ^a   Constantinidou, Anastasia ^a   Acland, Katharine ^a   Healy, Ciaran ^a   Harries, Mark ^b   O'Doherty, Michael ^b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

FDG; Fluorodeoxyglucose; Metastatic melanoma; Positron emission tomography; Response assessment

Indexed keywords

CISPLATIN; DACARBAZINE; FLUORODEOXYGLUCOSE F 18; VINBLASTINE; VINDESINE;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DRUG MONITORING; FEMALE; HIGH RISK PATIENT; HUMAN; MALE; MELANOMA; METABOLISM; METASTASIS; MULTIPLE CYCLE TREATMENT; TREATMENT RESPONSE;

ADULT; ANTINEOPLASTIC AGENTS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; PILOT PROJECTS; PROGNOSIS; RADIOPHARMACEUTICALS; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 37349084220     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/MNM.0b013e3282f1b97b     Document Type: Article

References (17)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, et al. Cancer statistics, 2006. CA Cancer J Clin 2006; 56:106-130.
2. Belhocine TZ, Scott AM, Even-Sapir E, Urbain JL, Essner R. Role of nuclear medicine in the management of cutaneous malignant melanoma. J Nucl Med 2006; 47:957-967.
3. Acland KM, Healy C, Calonje E, O'Doherty M, Nunan T, Page C, et al. Comparison of positron emission tomography scanning and sentinel node biopsy in the detection of micrometastases of primary cutaneous malignant melanoma. J Clin Oncol 2001; 19:2674-2678.
4. Larson SM, Schwartz LH. 18F-FDG PET as a candidate for ‘qualified biomarker’: functional assessment of treatment response in oncology. J Nucl Med 2006; 47:901-903.
5. 18F-fluorodeoxyglucose positron emission tomography: results of a prospective study of 100 patients. Cancer 1998; 82:1664-1671.
6. Stas M, Stroobants S, Dupont P, Gysen M, Hoe LV, Garmyn M, et al. 18-FDG PET scan in the staging of recurrent melanoma: additional value and therapeutic impact. Melanoma Res 2002; 12:479-490.
7. Prichard RS, Hill AD, Skehan SJ, O'Higgins NJ. Positron emission tomography for staging and management of malignant melanoma. Br J Surg 2002; 89:389-396.
8. Mijnhout GS, Hoekstra OS, van Tulder MW, Teule GJ, Deville WL. Systematic review of the diagnostic accuracy of (18)F-fluorodeoxyglucose positron emission tomography in melanoma patients. Cancer 2001; 91:1530-1542.
9. Swetter SM, Carroll LA, Johnson DL, Segall GM. Positron emission tomography is superior to computed tomography for metastatic detection in melanoma patients. Ann Surg Oncol 2002; 9:646-653.
10. 18F-FDG PET/CT imaging for N- and M-staging of malignant melanoma: experience with 250 consecutive patients. J Clin Oncol 2006; 24:1178-1187.
11. Tyler DS, Onaitis M, Kherani A, Hata A, Nicholson E, Keogan M, et al. Positron emission tomography scanning in malignant melanoma. Cancer 2000; 89:1019-1025.
12. Mitchell MS. Chemotherapy for melanoma: the resultant of conflicting vectors. J Clin Oncol 2004; 22:2043-2045.
13. Rass K, Tadler D, Tilgen W. Therapy of malignant melanoma: First-, second- and pathogenesis-oriented third-line therapies. Hautarzt 2006; 57:773-784.
14. Eisen T, Ahmad T, Flaherty KT, Gore M, Kaye S, Marais R, et al. Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br J Cancer 2006; 95:581-586.
15. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-216.
16. Schwaiger M, Peschel C. Biological imaging for selecting and monitoring cancer therapy; a pathway to individualised therapy. Eur J Nucl Med Mol Imaging 2006; 33(suppl 13):1-5.
17. Mercier GA, Alavi A, Fraker DL. FDG positron emission tomography in isolated limb perfusion therapy in patients with locally advanced melanoma: preliminary results. Clin Nucl Med 2001; 26:832-836.